| dc.contributor.advisor | Hutt, Peter Barton | en_US |
| dc.contributor.author | Kisloff, Michelle A. | en_US |
| dc.date.accessioned | 2012-06-07T04:01:00Z | |
| dc.date.issued | 1995 | en_US |
| dc.identifier.citation | The H2 Blockers' Rx-to OTC Switch: For Whom Will It Spell Relief? (1995 Third Year Paper) | en |
| dc.identifier.uri | http://nrs.harvard.edu/urn-3:HUL.InstRepos:8846781 | |
| dc.description.abstract | Tylenol. Advil. Monistat 7. Imodium AD. These are some of the most commonly used, widely available, and successful drugs in the United States. All of them began as drugs only available by a prescription. All of them made a successful prescription-only to over-the-counter (Rx-to-OTC) switch through the switch" mechanisms of the Food and Drug Administration (FDA). Due to the amount of money that pharmaceutical companies can make with an Rx-to-OTC switch, the FDA has received dozens of switch requests in the last few years, and it expects to receive many more in the near future. | en |
| dc.language.iso | en_US | en |
| dash.license | LAA | en_US |
| dc.subject | Food and Drug Law | en |
| dc.subject | H2 blockers | en |
| dc.subject | HZ blockers | en |
| dc.subject | Rx to OTC | en |
| dc.title | The H2 Blockers' Rx-to OTC Switch: For Whom Will It Spell Relief? | en |
| dc.type | Paper (for course/seminar/workshop) | en_US |
| dc.date.available | 2012-06-07T04:01:00Z | |
| dash.authorsordered | false | |
